SenzaGen AB is planning an IPO of its common shares on the Nasdaq First North in Stockholm.
The Lund, Sweden-based company is offering up to 4,645,000 shares to the public in Sweden and Denmark as well as institutional investors in Sweden and abroad. The shares are priced at 19.40 Swedish kronor each, corresponding to an offer amount of 90 million Swedish kronor.
Meanwhile, the part of the offer that will cater to the general public in Denmark will be limited to under €1 million.
The IPO values the company at about 210 million Swedish kronor.
The public can apply for the offer from Sept. 4 to Sept. 12, while the settlement date is Sept. 19. The first day of trading is expected to be Sept. 21, assuming the Nasdaq Stockholm AB approves the application.
SenzaGen develops tests for screening potential therapies.
As of Aug. 31, US$1 was equivalent to 7.97 Swedish kronor.